QUEST DIAGNOSTICS INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 140.4 USD | -0.32% |
|
+2.26% | +1.86% |
| 07-05 | Not too hot, not too cold |  |
| 07-05 | Baird Adjusts Price Target on Quest Diagnostics to $153 From $145, Maintains Neutral Rating | MT |
Quest Diagnostics is the world's leading provider of diagnostics testing and information service for patients and health professionals. Net sales break down by activity as follows:
- testing and diagnostic services (97.3%): routine clinical testing, gene-based testing and advanced diagnostic and anatomica pathology diagnostic services;
- other (2.7%).
Calendar
2024-07-07
- Détachement de
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
140.4
USD
Average target price
147.7
USD
Spread / Average Target
+5.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.86% | 15.65B | |
| +18.33% | 85.53B | |
| -28.29% | 71.18B | |
| +0.99% | 26.76B | |
| +3.67% | 17.43B | |
| -9.99% | 17.18B | |
| +79.98% | 13.71B | |
| +74.41% | 13.27B | |
| -25.09% | 13.1B | |
| +18.69% | 12.41B |
- Stock Market
- Equities
- DGX Stock
- News Quest Diagnostics Incorporated
- Quest Diagnostics to Buy LifeLabs From OMERS
